Market Overview

UPDATE: Bank of America Raises PO to $40 on Integra Lifesciences

Share:
Related IART
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed
Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B
Integra LifeSciences Holdings' (IART) CEO Pete Arduini on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Bank of America Merrill Lynch reiterates a Neutral rating on Integra Lifesciences (NASDAQ: IART) and raises its price objective from $36 to $40.

Bank of America Merrill Lynch comments, “Raising PO to $40 We are raising our PO on IART to $40 from $36 primarily due to the recent signs of stabilization and/or strength in IART's most important orthopedic growth markets (extremities/spine) that we have documented in recent notes on Biomet and ZMH. Additionally, IART, like many US-focused small cap device names, would benefit in a disproportionate way if the Supreme Court declares President Obama's healthcare reform law unconstitutional this week (a decision is expected Thursday 6/28).”

Integra Lifesciences closed at $35.74 yesterday.

Latest Ratings for IART

DateFirmActionFromTo
Jul 2016BarclaysMaintainsEqual-weight
Jul 2016JefferiesMaintainsBuy
Jul 2016JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color News Price Target Politics Legal Analyst Ratings General

 

Related Articles (IART)

View Comments and Join the Discussion!